Company Analysis
Sign in

Gelteq Limited (GELS)

Nasdaq: GELS · Pharmaceutical Preparations · filing with the SEC since 2022
Full chart Alerts Compare
Grade4.8
◀ Past 5.8● Present 4.7▶ Future 4.3
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
RevenueA$165,645+107.5%
Net income-A$6.6M-87.4%
Earnings per shareA$-0.72-63.6%
Operating cash flow-A$5.5M-415.8%
CashA$344,648+1305.5%
DebtA$4.2M+117.6%
Shareholders’ equityA$15.8M+4.6%
Shares, diluted9,272,375+14.2%
Return on equity-42.0%
The recordfrom its filings
Filings in 202610
Newest filingNov 2 · NT 20-F
Annual reportNov 17, 2025
Quarterly reportn/a
Next report due20-F by Oct 28 · overdue
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in AUD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton GELS · research, not advice